Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, IDYA, AKRO, ARVN, OCUL, and represent 30.87% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: RVMD (+$49M), ABVX (+$35M), VSTM (+$27M), PCVX (+$23M), PTGX (+$20M), AMLX (+$20M), Lb Pharmaceuticals (+$18M), CDTX (+$18M), QURE (+$18M), MAZE (+$16M).
- Started 22 new stock positions in COGT, QURE, ESPR, GUTS, PTGX, CMPX, IMRX, PEPG, TNGX, Lb Pharmaceuticals. ACLX, SRRK, CNTA, PCVX, DNTH, ALEC, KYMR, EPRX, MREO, AMLX, ABVX, PHVS.
- Reduced shares in these 10 stocks: , JAZZ (-$33M), TEVA (-$25M), , , KROS (-$18M), IDYA (-$18M), IRON (-$17M), RNA (-$15M), MDGL (-$15M).
- Sold out of its positions in ANNX, BCAX, CLDX, KRYS, LEGN, MDGL, MTSR, MLTX, NBIX, RAPP. XBI, TEVA, UTHR, XNCR, BHVN.
- Logos Global Management was a net buyer of stock by $23M.
- Logos Global Management has $1.1B in assets under management (AUM), dropping by 23.44%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Logos Global Management
Logos Global Management holds 56 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines Call Option (RVMD) | 11.5 | $128M | +61% | 2.8M | 46.70 |
|
| Ideaya Biosciences Call Option (IDYA) | 6.6 | $74M | -19% | 2.7M | 27.21 |
|
| Akero Therapeutics (AKRO) | 5.1 | $57M | 1.2M | 47.48 |
|
|
| Arvinas Ord (ARVN) | 4.3 | $48M | +16% | 5.6M | 8.52 |
|
| Ocular Therapeutix (OCUL) | 3.4 | $38M | +47% | 3.3M | 11.69 |
|
| Cidara Therapeutics Com New (CDTX) | 3.2 | $36M | +97% | 375k | 95.76 |
|
| Verastem Com New (VSTM) | 3.2 | $36M | +305% | 4.1M | 8.83 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.2 | $35M | NEW | 415k | 84.90 |
|
| Janux Therapeutics (JANX) | 3.1 | $35M | -4% | 1.4M | 24.44 |
|
| Erasca (ERAS) | 3.0 | $33M | 15M | 2.18 |
|
|
| Maze Therapeatics (MAZE) | 2.9 | $32M | +100% | 1.2M | 25.93 |
|
| Olema Pharmaceuticals (OLMA) | 2.8 | $31M | 3.2M | 9.79 |
|
|
| Immunocore Hldgs Ads (IMCR) | 2.8 | $31M | +47% | 850k | 36.33 |
|
| Dyne Therapeutics (DYN) | 2.7 | $30M | +26% | 2.4M | 12.65 |
|
| Disc Medicine (IRON) | 2.7 | $30M | -35% | 450k | 66.08 |
|
| Design Therapeutics (DSGN) | 2.5 | $28M | -13% | 3.7M | 7.53 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.4 | $26M | -55% | 200k | 131.80 |
|
| Avidity Biosciences Ord (RNA) | 2.3 | $26M | -36% | 600k | 43.57 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.1 | $24M | 850k | 28.00 |
|
|
| Apellis Pharmaceuticals Call Option (APLS) | 2.0 | $23M | 1.0M | 22.63 |
|
|
| Vaxcyte (PCVX) | 2.0 | $23M | NEW | 625k | 36.02 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.8 | $20M | +53% | 200k | 100.99 |
|
| Trevi Therapeutics (TRVI) | 1.8 | $20M | +158% | 2.2M | 9.15 |
|
| Protagonist Therapeutics (PTGX) | 1.8 | $20M | NEW | 300k | 66.43 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.8 | $20M | NEW | 1.5M | 13.59 |
|
| Lb Pharmaceuticals Com Shs | 1.6 | $18M | NEW | 1.1M | 15.79 |
|
| Uniqure Nv SHS (QURE) | 1.6 | $18M | NEW | 300k | 58.37 |
|
| Kymera Therapeutics (KYMR) | 1.3 | $14M | NEW | 250k | 56.60 |
|
| Biogen Idec (BIIB) | 1.3 | $14M | -50% | 100k | 140.08 |
|
| Arcellx Common Stock (ACLX) | 1.2 | $14M | NEW | 165k | 82.10 |
|
| Keros Therapeutics (KROS) | 1.2 | $13M | -57% | 850k | 15.82 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.1 | $13M | NEW | 525k | 24.25 |
|
| Larimar Therapeutics Call Option (LRMR) | 0.7 | $8.1M | 2.5M | 3.23 |
|
|
| Tango Therapeutics (TNGX) | 0.7 | $8.0M | NEW | 950k | 8.40 |
|
| Dianthus Therapeutics (DNTH) | 0.7 | $7.9M | NEW | 200k | 39.35 |
|
| Cogent Biosciences (COGT) | 0.6 | $7.2M | NEW | 500k | 14.36 |
|
| Compass Therapeutics (CMPX) | 0.6 | $7.2M | NEW | 2.1M | 3.50 |
|
| Crescent Biopharma (CBIO) | 0.6 | $7.1M | +8% | 600k | 11.89 |
|
| Enliven Therapeutics (ELVN) | 0.6 | $7.0M | -2% | 340k | 20.47 |
|
| Immuneering Corp Class A Com (IMRX) | 0.6 | $6.7M | NEW | 950k | 7.00 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.6 | $6.6M | -44% | 125k | 53.00 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.6 | $6.5M | NEW | 175k | 37.24 |
|
| Jade Biosciences Com New (JBIO) | 0.5 | $5.4M | 625k | 8.63 |
|
|
| Eupraxia Pharmaceuticals (EPRX) | 0.5 | $5.3M | NEW | 900k | 5.90 |
|
| Immunovant (IMVT) | 0.4 | $4.4M | 275k | 16.12 |
|
|
| Pharvaris N V (PHVS) | 0.3 | $3.7M | NEW | 150k | 24.95 |
|
| Astria Therapeutics (ATXS) | 0.3 | $3.6M | -28% | 500k | 7.28 |
|
| Pepgen (PEPG) | 0.3 | $3.5M | NEW | 750k | 4.62 |
|
| Aclaris Therapeutics (ACRS) | 0.3 | $2.9M | -18% | 1.5M | 1.90 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.2 | $2.1M | 474k | 4.36 |
|
|
| Esperion Therapeutics (ESPR) | 0.2 | $2.0M | NEW | 750k | 2.65 |
|
| Septerna (SEPN) | 0.1 | $1.6M | -23% | 84k | 18.81 |
|
| Alector Call Option (ALEC) | 0.1 | $1.5M | NEW | 500k | 2.96 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.1 | $1.0M | NEW | 500k | 2.06 |
|
| Fractyl Health (GUTS) | 0.1 | $795k | NEW | 500k | 1.59 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $14k | 67k | 0.20 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2025 Q3 filed Nov. 14, 2025
- Logos Global Management 2025 Q2 filed Aug. 14, 2025
- Logos Global Management 2025 Q1 filed May 15, 2025
- Logos Global Management 2024 Q4 filed Feb. 14, 2025
- Logos Global Management 2024 Q3 filed Nov. 14, 2024
- Logos Global Management 2024 Q2 amended filed Aug. 27, 2024
- Logos Global Management 2024 Q2 filed Aug. 14, 2024
- Logos Global Management 2024 Q1 filed May 15, 2024
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023
- Logos Global Management 2022 Q3 filed Nov. 14, 2022
- Logos Global Management 2022 Q2 filed Aug. 15, 2022
- Logos Global Management 2022 Q1 filed May 16, 2022